EA201892280A1 - Способы лечения селективными агонистами cb-рецептора - Google Patents

Способы лечения селективными агонистами cb-рецептора

Info

Publication number
EA201892280A1
EA201892280A1 EA201892280A EA201892280A EA201892280A1 EA 201892280 A1 EA201892280 A1 EA 201892280A1 EA 201892280 A EA201892280 A EA 201892280A EA 201892280 A EA201892280 A EA 201892280A EA 201892280 A1 EA201892280 A1 EA 201892280A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
receptor
treatment
selective agonists
apd371
Prior art date
Application number
EA201892280A
Other languages
English (en)
Inventor
Уилльям Шанахан
Original Assignee
Арена Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арена Фармасьютикалз, Инк. filed Critical Арена Фармасьютикалз, Инк.
Publication of EA201892280A1 publication Critical patent/EA201892280A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены способы лечения нарушения (например, боли, фиброза), связанного с CB-рецептором. Эти способы направлены на снижение риска нежелательных явлений вследствие сниженных артериального давления и/или частоты сердечных сокращений у субъектов, нуждающихся в лечении соединением-агонистом CB-рецептора (например, APD371).
EA201892280A 2016-04-10 2017-04-10 Способы лечения селективными агонистами cb-рецептора EA201892280A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320572P 2016-04-10 2016-04-10
PCT/US2017/026848 WO2017180528A1 (en) 2016-04-10 2017-04-10 Methods of treatment with selective cb2 receptor agonists

Publications (1)

Publication Number Publication Date
EA201892280A1 true EA201892280A1 (ru) 2019-04-30

Family

ID=60041951

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892280A EA201892280A1 (ru) 2016-04-10 2017-04-10 Способы лечения селективными агонистами cb-рецептора

Country Status (13)

Country Link
US (1) US20190160058A1 (ru)
EP (1) EP3452037A4 (ru)
JP (1) JP2019510806A (ru)
KR (1) KR20180128491A (ru)
CN (1) CN109310673A (ru)
AU (1) AU2017249211A1 (ru)
BR (1) BR112018070786A2 (ru)
CA (1) CA3019842A1 (ru)
EA (1) EA201892280A1 (ru)
IL (1) IL262135A (ru)
MX (1) MX2018012361A (ru)
UA (1) UA124626C2 (ru)
WO (1) WO2017180528A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208847A1 (en) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
KR20200005614A (ko) * 2017-05-08 2020-01-15 아레나 파마슈티칼스, 인크. 내장 통증의 치료를 위한 화합물 및 방법
US11607275B2 (en) * 2019-05-20 2023-03-21 Medtronic Ireland Manufacturing Unlimited Company Selection of hypertensive patients for treatment with renal denervation
US20240165109A1 (en) * 2021-03-02 2024-05-23 Arena Pharmaceuticals, Inc. Methods of Treatment with Selective CB2 Receptor Agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
US7308894B2 (en) * 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
IL150302A (en) * 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
WO2003063758A2 (en) * 2002-01-31 2003-08-07 Pharmos Corporation Bicyclic cb2 cannabinoid receptor ligands
US8044071B2 (en) * 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
KR20200008045A (ko) * 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
MX346644B (es) * 2011-02-25 2017-03-14 Arena Pharm Inc Moduladores de receptores canabinoides.
EP2678330A1 (en) * 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Also Published As

Publication number Publication date
MX2018012361A (es) 2019-05-30
KR20180128491A (ko) 2018-12-03
US20190160058A1 (en) 2019-05-30
CN109310673A (zh) 2019-02-05
EP3452037A4 (en) 2020-03-11
IL262135A (en) 2018-11-29
WO2017180528A1 (en) 2017-10-19
EP3452037A1 (en) 2019-03-13
UA124626C2 (uk) 2021-10-20
AU2017249211A1 (en) 2018-11-22
BR112018070786A2 (pt) 2019-02-05
JP2019510806A (ja) 2019-04-18
CA3019842A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
MX2021014748A (es) Kits, dispositivos descartables para reducir el oxigeno y metodos para usarlos.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA201892280A1 (ru) Способы лечения селективными агонистами cb-рецептора
EA201992474A2 (ru) Агонисты 5ht для лечения нарушений
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX2019003710A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
HUE052395T2 (hu) Benzimidazol-származékok mint NAV 1.7 (nátriumcsatorna, feszültségkapuzott, IX típusú, alfa alegység (SCN9A) inhibitorok fájdalom, diszúria és szklerózis multiplex kezelésére
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201691525A1 (ru) Применение кладрибина для лечения оптиконевромиелита
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
MX2016003525A (es) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
MY194135A (en) Treatment and diagnosis of inflammatory disorders